VISTA blockade reprograms macrophages to an M1-like phenotype and allows for immune priming, which synergizes with PD-L1 inhibition to promote T cell–mediated tumor control in preclinical PDAC models (169, 170, 173). This evidence concerns the gene VSIR and neoplasm.